IL289166A - Anti-lrrc25 preparations and methods for modulating inflammatory phenotypes of myeloid cells and their use - Google Patents

Anti-lrrc25 preparations and methods for modulating inflammatory phenotypes of myeloid cells and their use

Info

Publication number
IL289166A
IL289166A IL289166A IL28916621A IL289166A IL 289166 A IL289166 A IL 289166A IL 289166 A IL289166 A IL 289166A IL 28916621 A IL28916621 A IL 28916621A IL 289166 A IL289166 A IL 289166A
Authority
IL
Israel
Prior art keywords
lrrc25
compositions
methods
myeloid cell
cell inflammatory
Prior art date
Application number
IL289166A
Other languages
English (en)
Hebrew (he)
Original Assignee
Verseau Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Verseau Therapeutics Inc filed Critical Verseau Therapeutics Inc
Publication of IL289166A publication Critical patent/IL289166A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
IL289166A 2019-06-27 2021-12-20 Anti-lrrc25 preparations and methods for modulating inflammatory phenotypes of myeloid cells and their use IL289166A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962867593P 2019-06-27 2019-06-27
PCT/US2020/038115 WO2020263650A1 (en) 2019-06-27 2020-06-17 Anti-lrrc25 compositions and methods for modulating myeloid cell inflammatory phenotypes and uses thereof

Publications (1)

Publication Number Publication Date
IL289166A true IL289166A (en) 2022-02-01

Family

ID=74060354

Family Applications (1)

Application Number Title Priority Date Filing Date
IL289166A IL289166A (en) 2019-06-27 2021-12-20 Anti-lrrc25 preparations and methods for modulating inflammatory phenotypes of myeloid cells and their use

Country Status (10)

Country Link
US (1) US20220363752A1 (https=)
EP (1) EP3990017A4 (https=)
JP (1) JP2022539038A (https=)
KR (1) KR20220042131A (https=)
CN (1) CN114423452A (https=)
AU (1) AU2020306772A1 (https=)
BR (1) BR112021026411A2 (https=)
CA (1) CA3142838A1 (https=)
IL (1) IL289166A (https=)
WO (1) WO2020263650A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3267340A1 (en) * 2022-10-05 2024-04-11 Shangpharma Innovation, Inc. Anti-urokinase type plasminogen activator receptor antibodies and methods of use
CN116380755B (zh) * 2023-03-20 2023-11-21 广州市第一人民医院（广州消化疾病中心、广州医科大学附属市一人民医院、华南理工大学附属第二医院） CD127+PMN-MDSCs在诊断支气管肺发育不良中的应用及诊断试剂盒

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101122628B1 (ko) * 2009-02-16 2012-04-12 한국화학연구원 노닐페놀에 의해 유도된 생식독성 진단용 바이오마커 및 이를 이용한 생식독성 진단 방법
US10279018B2 (en) * 2012-12-03 2019-05-07 Unity Biotechnology, Inc. Immunogenic compositions for inducing an immune response for elimination of senescent cells
WO2016203053A2 (en) * 2015-06-18 2016-12-22 Thomas Mole Herd Methods of characterising cancer
WO2017004153A1 (en) * 2015-06-29 2017-01-05 The Broad Institute Inc. Tumor and microenvironment gene expression, compositions of matter and methods of use thereof
JP7078533B2 (ja) * 2015-10-21 2022-05-31 オーエスイー イムノセラピューティクス 炎症促進性細胞へのマクロファージ分極を改変して癌を治療するための抗ＳＩＲＰａ化合物
CN109313201B (zh) * 2016-06-14 2022-04-01 高级生物设计公司 用于监测细胞凋亡的特异于γ-谷氨酰基-L-ε-赖氨酸(GGEL)的单克隆抗体
US20190233534A1 (en) * 2016-07-14 2019-08-01 Fred Hutchinson Cancer Research Center Multiple bi-specific binding domain constructs with different epitope binding to treat cancer
JP2021529753A (ja) * 2018-06-29 2021-11-04 ヴェルソー セラピューティクス， インコーポレイテッド 単球及びマクロファージの炎症性表現型を調節するための組成物及び方法、ならびにそれを使用する免疫療法

Also Published As

Publication number Publication date
EP3990017A4 (en) 2023-04-26
BR112021026411A2 (pt) 2022-03-15
AU2020306772A1 (en) 2022-02-17
EP3990017A1 (en) 2022-05-04
CN114423452A (zh) 2022-04-29
JP2022539038A (ja) 2022-09-07
US20220363752A1 (en) 2022-11-17
WO2020263650A1 (en) 2020-12-30
CA3142838A1 (en) 2020-12-30
KR20220042131A (ko) 2022-04-04

Similar Documents

Publication Publication Date Title
IL288511A (en) Anti-siglec-9 preparations and methods for modulating inflammatory myeloid cell phenotypes and uses thereof
IL320642B1 (en) Preparations and methods for engineering T cells
IL288510A (en) Anti-psgl-1 preparations and methods for modulating inflammatory myeloid cell phenotypes and uses thereof
IL287874A (en) Preparations and methods for producing t cells
IL275263A (en) Preparations and methods for inhibiting T cell exhaustion
SG11202008659TA (en) Cartyrin compositions and methods for use
SG11202004116QA (en) T cell manufacturing compositions and methods
GB2608279B (en) Therapeutic cell compositions and methods for manufacture and uses thereof
IL282447A (en) Methods and preparations for healing eye cell
IL291622A (en) Compositions comprising regulatory t cells and methods of making and using them
IL277878A (en) Preparations and methods for stem cell transplantation
SG11202100600YA (en) Compositions and related methods for agriculture
SG11202104611YA (en) T cell compositions with improved phenotypic properties
KR102325857B9 (ko) 조절 t 세포 배양용 조성물 및 이의 용도
IL290109A (en) Cells for enhanced immune healing and their uses
SG11202106857VA (en) Compositions and methods for inhibiting hmgb1 expression
SG11202102538RA (en) Compositions and methods for transfecting cells
IL289166A (en) Anti-lrrc25 preparations and methods for modulating inflammatory phenotypes of myeloid cells and their use
IL290325A (en) Biopharmaceutical preparations and related methods
PL3899996T3 (pl) Kompozycje elektrolitowe
GB201817450D0 (en) Battery composition
HK40074197A (en) Anti-cd53 compositions and methods for modulating myeloid cell inflammatory phenotypes and uses thereof
HK40074196A (en) Anti-lrrc25 compositions and methods for modulating myeloid cell inflammatory phenotypes and uses thereof
HK40072877A (en) Anti-siglec-9 compositions and methods for modulating myeloid cell inflammatory phenotypes and uses thereof
IL289564A (en) Modified cells and related methods